| abstract |
Disclosed are 1,2,3,4-tetrahydro-cyclopenta[b]indols as represented by the general formula (I), wherein R1 represents cyano, -CH=NOCH3, -OCHF2, or -OCF3; R2 represents -COR2a or -SO2R2b; R2a represents alkyl, alkoxy, cyclopropyl, or -NRaRb; R2b represents alkyl, cyclopropyl, or -NRaRb; Ra and Rb each independently represent hydrogen or alkyl; and R3 represents a heteroaryl group selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, and thiadiazolyl, each of which is optionally substituted with 1 or 2 substituents independently selected from methyl, ethyl, bromo, chloro, fluoro, -CHF2, -CF3, hydroxy, amino, and -NHCH2CO2H; or a pharmaceutically acceptable salt thereof. Of particular importance is the compound (S)-(7-cyano-4-pyridin-2-ylmethyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-2-yl)-carbamic acid isopropyl ester. Further disclosed is a medicament which comprises a compound as defined above for use in the treatment of hypogonadism, reduced bone mass or density, osteoporosis, osteopenia, reduced muscle mass or strength, sarcopenia, Age Related Functional Decline, delayed puberty in boys, anaemia, male or female sexual dysfunction, erectile dysfunction, reduced libido, depression, or lethargy. |